Ceftolozane/tazobactam 187 activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing 188 urinary tract and intraabdominal infections in Europe: report from an antimicrobial 189 surveillance programme (2012-15), J Antimicrob Chemother, vol.72, issue.5, pp.1386-1395, 2017. ,
,
, , 2000.
, A novel class A extended-spectrum beta-lactamase (BES-1) in Serratia marcescens 193 isolated in Brazil, Antimicrob Agents Chemother, vol.44, issue.11, pp.3061-3069
, , p.195
, , 2004.
, Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of 197 the Auvergne, France: a 2 year prospective study, J Antimicrob Chemother, vol.54, issue.3, pp.634-643
Detection of plasmid-mediated AmpC beta-lactamase 199 genes in clinical isolates by using multiplex PCR, J Clin Microbiol, vol.40, issue.6, pp.2153-62, 2002. ,
, Leyssene, vol.202
, , p.204, 2017.
, France as Assessed by a Multicenter Study, Antimicrob Agents Chemother, vol.61, issue.3, pp.205-01911
, Antimicrobial Activity, p.207, 2017.
Tested Against Enterobacteriaceae and Pseudomonas 208 aeruginosa with Various Resistance Patterns ,
, Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam 210
, Susceptibility. Microb Drug Resist, vol.17
, Vitro Activity of Ceftolozane Alone and in 212 Combination with Tazobactam against Extended-Spectrum-?-Lactamase-Harboring, p.213, 2015.
, Antimicrob Agents Chemother, vol.59, issue.8, pp.4521-4526
,
, , p.216
BSAC Resistance Surveillance Standing Committee. Activity 217 of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, p.218, 2017. ,
, Pseudomonas aeruginosa and non-fermenters from the British Isles, J Antimicrob 219 Chemother, vol.72, issue.8, pp.2278-2289